Recent News

• 12.09.2025 - ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
• 12.09.2025 - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
• 12.09.2025 - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
• 12.08.2025 - ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
• 12.06.2025 - Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
• 12.05.2025 - Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
• 12.01.2025 - Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
• 11.25.2025 - Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Recent Filings

• 12.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.09.2025 - EX-99.1 EX-99.1
• 12.08.2025 - EX-99.1 EX-99.1
• 12.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.05.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.01.2025 - EX-99.1 EX-99.1
• 12.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.28.2025 - EX-99.1 EX-99.1